(RCUS) Arcus Biosciences - Overview
Stock: Cancer, Antibody, Inhibitor, Clinical, Pipeline
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 62.7% |
| Relative Tail Risk | -6.54% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.06 |
| Alpha | 42.18 |
| Character TTM | |
|---|---|
| Beta | 1.379 |
| Beta Downside | 1.034 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.82% |
| CAGR/Max DD | 0.03 |
Description: RCUS Arcus Biosciences January 20, 2026
Arcus Biosciences (NYSE:RCUS) is a clinical-stage biopharma focused on developing and eventually commercializing oncology therapeutics in the United States. Incorporated in 2015 and headquartered in Hayward, California, the firm operates under a common-stock structure within the Biotechnology sub-industry.
The company’s lead assets include Casdatifan, a HIF-2α inhibitor targeting renal cell carcinoma, and Domvanalimab, an anti-TIGIT antibody currently in Phase 2 (lung cancer) and Phase 3 (gastro-intestinal cancers) trials. Additional candidates span the adenosine-axis (Quemliclustat, Etrumadenant), checkpoint inhibition (Zimberelimab), CD39 targeting (AB598), and AXL inhibition (AB801), with trial phases ranging from Phase 1 to Phase 3 across lung, pancreatic, colorectal, and renal indications.
Arcus has secured strategic collaborations that de-risk development costs: a partnership with AstraZeneca supports the Phase 3 PACIFIC-8 trial (Domvanalimab + Durvalumab in Stage 3 NSCLC) and a Phase 1/1b study of Casdatifan + Volrustomig in treatment-naïve clear-cell RCC; BVF Partners backs discovery programs for inflammatory diseases. As of the latest 10-Q, the company reported a cash runway of roughly $150 million, with a quarterly burn rate of ≈ $30 million, implying ~5 quarters of liquidity absent additional financing.
Sector-level drivers that could influence Arcus’s valuation include the rapid growth of immuno-oncology (global market projected to exceed $150 billion by 2028) and a rising investor appetite for niche checkpoint targets such as TIGIT and CD39. However, the company’s valuation remains highly sensitive to trial readouts; a positive Phase 3 result for Domvanalimab could materially lift the market cap, while any delay or negative outcome would likely compress it.
For a deeper, data-driven assessment of RCUS’s risk-adjusted upside, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -349.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.48 > 0.02 and ΔFCF/TA -34.14 > 1.0 |
| NWC/Revenue: 259.2% < 20% (prev 346.8%; Δ -87.60% < -1%) |
| CFO/TA -0.47 > 3% & CFO -462.0m > Net Income -349.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (106.5m) vs 12m ago 16.52% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 21.56% > 50% (prev 21.01%; Δ 0.56% > 0%) |
| Interest Coverage Ratio: -41.62 > 6 (EBITDA TTM -323.0m / Interest Expense TTM 8.00m) |
Altman Z'' -1.59
| A: 0.64 (Total Current Assets 857.0m - Total Current Liabilities 235.0m) / Total Assets 974.0m |
| B: -1.42 (Retained Earnings -1.38b / Total Assets 974.0m) |
| C: -0.30 (EBIT TTM -333.0m / Avg Total Assets 1.11b) |
| D: 0.81 (Book Value of Equity 436.0m / Total Liabilities 538.0m) |
| Altman-Z'' Score: -1.59 = D |
Beneish M -3.05
| DSRI: 0.73 (Receivables 14.0m/21.0m, Revenue 240.0m/263.0m) |
| GMI: 0.99 (GM 97.08% / 96.20%) |
| AQI: 1.25 (AQ_t 0.08 / AQ_t-1 0.06) |
| SGI: 0.91 (Revenue 240.0m / 263.0m) |
| TATA: 0.12 (NI -349.0m - CFO -462.0m) / TA 974.0m) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of RCUS shares?
Over the past week, the price has changed by -2.45%, over one month by +0.57%, over three months by +8.58% and over the past year by +69.72%.
Is RCUS a buy, sell or hold?
- StrongBuy: 8
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RCUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33 | 56.2% |
| Analysts Target Price | 33 | 56.2% |
| ValueRay Target Price | 23.3 | 10% |
RCUS Fundamental Data Overview February 03, 2026
P/B = 6.1836
Revenue TTM = 240.0m USD
EBIT TTM = -333.0m USD
EBITDA TTM = -323.0m USD
Long Term Debt = 98.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.0m USD (from shortTermDebt, last quarter)
Debt = 111.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -127.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.88b USD (2.60b + Debt 111.0m - CCE 831.0m)
Interest Coverage Ratio = -41.62 (Ebit TTM -333.0m / Interest Expense TTM 8.00m)
EV/FCF = -4.06x (Enterprise Value 1.88b / FCF TTM -464.0m)
FCF Yield = -24.64% (FCF TTM -464.0m / Enterprise Value 1.88b)
FCF Margin = -193.3% (FCF TTM -464.0m / Revenue TTM 240.0m)
Net Margin = -145.4% (Net Income TTM -349.0m / Revenue TTM 240.0m)
Gross Margin = unknown ((Revenue TTM 240.0m - Cost of Revenue TTM 7.00m) / Revenue TTM)
Tobins Q-Ratio = 1.93 (Enterprise Value 1.88b / Total Assets 974.0m)
Interest Expense / Debt = 2.70% (Interest Expense 3.00m / Debt 111.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -263.1m (EBIT -333.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.65 (Total Current Assets 857.0m / Total Current Liabilities 235.0m)
Debt / Equity = 0.25 (Debt 111.0m / totalStockholderEquity, last quarter 436.0m)
Debt / EBITDA = 0.39 (negative EBITDA) (Net Debt -127.0m / EBITDA -323.0m)
Debt / FCF = 0.27 (negative FCF - burning cash) (Net Debt -127.0m / FCF TTM -464.0m)
Total Stockholder Equity = 500.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.36% (Net Income -349.0m / Total Assets 974.0m)
RoE = -69.77% (Net Income TTM -349.0m / Total Stockholder Equity 500.2m)
RoCE = -55.66% (EBIT -333.0m / Capital Employed (Equity 500.2m + L.T.Debt 98.0m))
RoIC = -45.91% (negative operating profit) (NOPAT -263.1m / Invested Capital 573.0m)
WACC = 10.64% (E(2.60b)/V(2.71b) * Re(11.0%) + D(111.0m)/V(2.71b) * Rd(2.70%) * (1-Tc(0.21)))
Discount Rate = 11.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.16%
Fair Price DCF = unknown (Cash Flow -464.0m)
EPS Correlation: 35.99 | EPS CAGR: 38.07% | SUE: 2.48 | # QB: 1
Revenue Correlation: 1.64 | Revenue CAGR: -50.18% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.01 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.85 | Chg30d=+0.015 | Revisions Net=+2 | Growth EPS=-10.1% | Growth Revenue=-54.5%